The latest trading session saw AbbVie (ABBV) ending at $164.25, denoting a +1.05% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 0.12%, and the technology-centric Nasdaq decreased by 1.15%.Prior to today's trading, shares of the drugmaker had lost 9.53% over the past month. This has lagged the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.Market participants will be cl ...

Blue-chip dividend stocks have always been relevant. While they’re not the most exciting investments, they provide a steady hand during market uncertainty. This attribute has just become even more critical.With an already tense situation in the geopolitical realm boiling over, investors will likely seek reassurances. It doesn’t get much better than established stalwarts that pay consistent and/or reliable passive income. On this note, below are top blue-chip dividend stocks to consider.RTX (RTX)Source: JHVE ...

Everything is going according to plan, and more growth is on the way.Big pharma stocks like AbbVie (ABBV -2.22%) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the news for good reasons, and despite relying on the lifesaving medicines that they produce, most people aren't talking to their coworkers about how their products are going to be in every household or core enablers for some grand global trend.But a ...

vzphotos Investment thesis AbbVie (NYSE:ABBV) is a profitability superstar, generating almost 40% in free cash flow margin even when I deduct stock-based compensation. The company has a stellar revenue growth trajectory over the past decade, which was fueled mostly by strategic acquisitions. The approach is aggressive, but AbbVie's strong track record of success increases my confidence in future growth. AbbVie has a diverse portfolio of products across several promising drug markets. The valuation looks ...

PM Images Shareholders of AbbVie Inc. (NYSE:ABBV) should be thrilled with its overall results, as just the appreciation over the past decade has outperformed the market. Shares of ABBV have appreciated by 248.90% over the past decade and by 104.87% over the past 5 years. The SPDR S&P 500 ETF Trust (SPY), which is what I use to track the market, has appreciated by 78.52% over the past 5 years, and by 175.83% over the past decade. ABBV is one of those companies that continues to outpace the market, and when t ...

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine-     Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment-     Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science NORTH CHI ...

AbbVie (ABBV) closed the latest trading day at $167.52, indicating a -0.89% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.The drugmaker's stock has dropped by 6.02% in the past month, falling short of the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.Investors will be eagerly watching for the performance of AbbVie in its upcoming earning ...

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally. Many small-cap biotech stocks are being held back by the Fed’s more restrictive stance on interest rates. But even some of the large-cap names with commercially available drugs that are household names are also underperforming the market. But “some” isn’t the same as “all.” In a stock picker’s market, you want to find the stocks that have a chance to outperform. One way to find thes ...

From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow® IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people w ...

Income-seeking investors can look forward to steady payout raises from these pharma stocks.If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions. Healthcare expenses are generally unavoidable, which makes it a great sector to look for stocks with steadily rising dividend payouts.AbbVie (ABBV -0.12%), Bristol Myers Squibb (BMY -0.43%), and Johnson & Johnson (JNJ -0.53%) a ...